• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's After-Market Session

    7/21/23 5:32:14 PM ET
    $ALXO
    $BDRX
    $BDX
    $BPTS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALXO alert in real time by email

    Gainers

    • Virpax Pharmaceuticals (NASDAQ:VRPX) stock moved upwards by 9.6% to $1.0 during Friday's after-market session. The market value of their outstanding shares is at $11.6 million.
    • Nuwellis (NASDAQ:NUWE) shares rose 8.77% to $2.48. The market value of their outstanding shares is at $2.9 million.
    • NanoVibronix (NASDAQ:NAOV) shares rose 8.35% to $3.5. The company's market cap stands at $5.8 million.
    • Greenwich LifeSciences (NASDAQ:GLSI) stock rose 6.84% to $9.72. The market value of their outstanding shares is at $124.9 million.
    • Becton, Dickinson (NYSE:BDX) shares increased by 6.63% to $282.4. Today's trading volume for this security ended up closing at 72.5K shares, which is 6.5 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $80.2 billion.
    • Ra Medical Systems (AMEX:RMED) shares increased by 6.5% to $0.72. The company's market cap stands at $4.6 million.

    Losers

    • ALX Oncology Holdings (NASDAQ:ALXO) stock fell 12.3% to $5.9 during Friday's after-market session. The market value of their outstanding shares is at $241.1 million.
    • ViewRay (NASDAQ:VRAY) stock fell 11.02% to $0.05. Today's trading volume for this security ended up closing at 6.8 million shares, which is 65.6 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $9.6 million.
    • Verrica Pharmaceuticals (NASDAQ:VRCA) shares decreased by 10.8% to $6.65. At the close, Verrica Pharmaceuticals's trading volume reached 285.6K shares. This is 120.4% of its average volume over the last 100 days. The company's market cap stands at $278.3 million.
    • Biophytis (NASDAQ:BPTS) shares declined by 8.74% to $2.09. The company's market cap stands at $6.5 million.
    • InspireMD (NASDAQ:NSPR) shares fell 8.54% to $3.0. The market value of their outstanding shares is at $63.5 million.
    • Biodexa Pharmaceuticals (NASDAQ:BDRX) shares fell 8.4% to $5.13. The market value of their outstanding shares is at $1.2 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ALXO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALXO
    $BDRX
    $BDX
    $BPTS

    CompanyDatePrice TargetRatingAnalyst
    ALX Oncology Holdings Inc.
    $ALXO
    3/19/2026$5.00Overweight
    Wells Fargo
    ALX Oncology Holdings Inc.
    $ALXO
    3/6/2026$6.00Buy
    UBS
    Becton Dickinson and Company
    $BDX
    2/10/2026$202.00Overweight
    Barclays
    Becton Dickinson and Company
    $BDX
    2/3/2026$233.00Buy
    Citigroup
    InspireMD Inc.
    $NSPR
    2/2/2026$6.00Buy
    Maxim Group
    ALX Oncology Holdings Inc.
    $ALXO
    11/13/2025$4.00Buy
    Jefferies
    Becton Dickinson and Company
    $BDX
    9/25/2025$211.00Sector Perform
    RBC Capital Mkts
    Greenwich LifeSciences Inc.
    $GLSI
    8/20/2025$45.00Outperform
    Noble Capital Markets
    More analyst ratings

    $ALXO
    $BDRX
    $BDX
    $BPTS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wells Fargo initiated coverage on ALX Oncology with a new price target

    Wells Fargo initiated coverage of ALX Oncology with a rating of Overweight and set a new price target of $5.00

    3/19/26 8:25:33 AM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    UBS resumed coverage on ALX Oncology with a new price target

    UBS resumed coverage of ALX Oncology with a rating of Buy and set a new price target of $6.00

    3/6/26 8:38:03 AM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays resumed coverage on Becton Dickinson with a new price target

    Barclays resumed coverage of Becton Dickinson with a rating of Overweight and set a new price target of $202.00

    2/10/26 7:21:54 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $ALXO
    $BDRX
    $BDX
    $BPTS
    SEC Filings

    View All

    SEC Form 20-F filed by Biodexa Pharmaceuticals plc American Depositary Shs

    20-F - Biodexa Pharmaceuticals Plc (0001643918) (Filer)

    3/27/26 5:09:45 PM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Biodexa Pharmaceuticals plc American Depositary Shs

    6-K - Biodexa Pharmaceuticals Plc (0001643918) (Filer)

    3/27/26 5:00:06 PM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuwellis Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Nuwellis, Inc. (0001506492) (Filer)

    3/27/26 4:55:30 PM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ALXO
    $BDRX
    $BDX
    $BPTS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Preliminary Results for the Year Ended 31 December 2025

    March 27, 2026 Biodexa Pharmaceuticals PLC("Biodexa" or the "Company" or, together with its subsidiaries, the "Group") Preliminary Results for the Year Ended 31 December 2025 Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical-stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers, announces its audited preliminary results for the year ended 31 December 2025. For more information, please contact: Biodexa Pharmaceuticals PLC Stephen Stamp, CEO Fiona Sharp, CFOTel: +44 (0)29 2048 0180www.biodexapharma.com About Biodexa The Company's lead development programs include eRapa, under development for Familial Adenoma

    3/27/26 5:00:00 PM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biodexa Launches Global Early Access Program for eRapa for FAP Patients Through Strategic Partnership with Tanner Pharma Group

    March 23, 2026 Biodexa Launches Global Early Access Program for eRapa for FAP Patients Through Strategic Partnership with Tanner Pharma Group Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers is pleased to announce that it has entered into a strategic partnership with Tanner Pharma Group to make eRapa available for Familial Adenomatous Polyposis (FAP) patients via an Early Access Program and Named Patient prescribing. This initiative gives clinicians who treat FAP patients the opportunity to prescribe this investigational medicine outside of a clinical trial

    3/23/26 8:30:00 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Greenwich LifeSciences Announces Addition of City of Hope to FLAMINGO-01

    STAFFORD, Texas, March 19, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the initiation of new clinical sites in the US. The Phase III clinical trial has recently been activated at City of Hope, one of the largest and most advanced cancer research and treatment organizations in the United States – specifically at its network sites in Los Angeles and Orange counties, Arizona, Atlanta, and Illinois. Principal investigator at City of Hop

    3/19/26 6:00:00 AM ET
    $GLSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALXO
    $BDRX
    $BDX
    $BPTS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Feld Michael

    4 - BECTON DICKINSON & CO (0000010795) (Issuer)

    3/27/26 1:49:58 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Pinto Shelly

    4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)

    3/23/26 4:05:04 PM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Lettmann Jason

    4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)

    3/23/26 4:05:08 PM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALXO
    $BDRX
    $BDX
    $BPTS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Director Stuka Paul bought $4,905 worth of shares (2,710 units at $1.81), increasing direct ownership by 0.70% to 391,628 units (SEC Form 4)

    4/A - InspireMD, Inc. (0001433607) (Issuer)

    2/23/26 4:05:19 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    Director Goodman Corey S bought $4,999,999 worth of shares (3,184,713 units at $1.57) (SEC Form 4)

    4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)

    2/4/26 4:15:59 PM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO and CFO Patel Snehal bought $53,694 worth of shares (1,800 units at $29.83), increasing direct ownership by 0.03% to 5,604,102 units (SEC Form 4)

    4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)

    1/15/26 6:05:06 AM ET
    $GLSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALXO
    $BDRX
    $BDX
    $BPTS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for YCANTH issued to VERRICA PHARMACEUTICALS INC

    Submission status for VERRICA PHARMACEUTICALS INC's drug YCANTH (ORIG-1) with active ingredient CANTHARIDIN has changed to 'Approval' on 07/21/2023. Application Category: NDA, Application Number: 212905, Application Classification: Type 5 - New Formulation or New Manufacturer

    7/21/23 4:54:32 PM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    November 23, 2021 - Coronavirus (COVID-19) Update: November 23, 2021

    For Immediate Release: November 23, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: On Nov. 22, the FDA authorized three over-the-counter (OTC) COVID-19 antigen diagnostic tests for people age 14 years or older with a self-collected nasal swab sample or people age 2 years or older when an adult collects the nasal swa

    11/23/21 3:16:12 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    July 23, 2021 - Coronavirus (COVID-19) Update: July 23, 2021

    For Immediate Release: July 23, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: The agency updated its FDA COVID-19 Response At-A-Glance Summary, which provides a quick look at facts, figures and highlights on the FDA's response efforts. On Thursday, July 22 the FDA issued an Emergency Use Authorization (EUA) to Bec

    7/23/21 4:06:11 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $ALXO
    $BDRX
    $BDX
    $BPTS
    Leadership Updates

    Live Leadership Updates

    View All

    Preliminary Results for the Year Ended 31 December 2025

    March 27, 2026 Biodexa Pharmaceuticals PLC("Biodexa" or the "Company" or, together with its subsidiaries, the "Group") Preliminary Results for the Year Ended 31 December 2025 Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical-stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers, announces its audited preliminary results for the year ended 31 December 2025. For more information, please contact: Biodexa Pharmaceuticals PLC Stephen Stamp, CEO Fiona Sharp, CFOTel: +44 (0)29 2048 0180www.biodexapharma.com About Biodexa The Company's lead development programs include eRapa, under development for Familial Adenoma

    3/27/26 5:00:00 PM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuwellis Appoints Dr. Stuart L. Goldstein as Director of Clinical Strategy to Advance Pediatric and Cardiorenal Strategy

    MINNEAPOLIS, March 05, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of Stuart L. Goldstein, MD, FASN as Director of Clinical Strategy. Dr. Goldstein is internationally recognized as a pioneer in pediatric nephrology and critical care medicine. He serves as Director of the Center for Acute Care Nephrology, holds the Clark D. West Endowed Chair in Pediatric Nephrology at Cincinnati Children's Hospital Medical Center and is Professor of Pediatrics at the University of Cincinnati College of Medicine. His work has helped define the modern understand

    3/5/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Nuwellis Appoints David A. McDonald and Martin J. Emerson to Board of Directors

    MINNEAPOLIS, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of David A. McDonald and Martin J. Emerson to its Board of Directors, effective February 24, 2026. The appointments strengthen the Company's board with complementary expertise in public company leadership, capital markets, and medical device commercialization. "These appointments reflect our continued focus on operational discipline and long-term value creation," said John Erb, President and CEO of Nuwellis. "Marty has led multiple medical device organizations through scali

    2/26/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ALXO
    $BDRX
    $BDX
    $BPTS
    Financials

    Live finance-specific insights

    View All

    InspireMD Reports Fourth Quarter and Full Year 2025 Financial Results

    MIAMI, March 18, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced financial and operating results for the fourth quarter and year ended December 31, 2025. Recent Business Highlights: Generated revenue of $3.1 million in the fourth quarter of 2025, up 62% year-over-year.Sustained strong commercial traction in the U.S. with the launch of CGuard Prime and continued growth in international demand for CGuard.Supported over 500 cumulative carotid procedures utilizing CGuard Prime across leading hospitals and integrated delivery networks since launch.Co

    3/18/26 7:00:00 AM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    Nuwellis, Inc. Announces Fourth Quarter and Full Year 2025 Financial Results

    MINNEAPOLIS, March 10, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter and Recent Highlights: Fourth quarter revenue of $2.4 million, a 4% increase compared to the prior-year quarter and 9% increase sequentially.208% increase in U.S. console sales in Q4 versus prior year quarter.Heart Failure revenue increased 48% and Pediatrics increased 16% year-over-year in Q4.Gross margin of 68.2% in Q4, compared to 58.4% in the prior-year quarter.Closed a $5.0 million private p

    3/10/26 8:15:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    InspireMD to Announce Fourth Quarter and Full Year 2025 Financial Results

    MIAMI, March 09, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that it will release its fourth quarter and full year 2025 financial results on Wednesday, March 18, 2026. In conjunction with the release, InspireMD will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss its financial results and recent highlights. A live audio webcast and an archive of the recording will be available through the Investors page of InspireMD's corporate website at https://investors.inspiremd.com. Interested participants are encouraged to register more than 15 minutes before the star

    3/9/26 9:00:00 AM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    $ALXO
    $BDRX
    $BDX
    $BPTS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Verrica Pharmaceuticals Inc.

    SC 13G/A - Verrica Pharmaceuticals Inc. (0001660334) (Subject)

    12/9/24 6:22:49 PM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by InspireMD Inc.

    SC 13G - InspireMD, Inc. (0001433607) (Subject)

    12/4/24 4:31:06 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13D/A filed by Verrica Pharmaceuticals Inc.

    SC 13D/A - Verrica Pharmaceuticals Inc. (0001660334) (Subject)

    11/26/24 4:15:26 PM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care